The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study.

Bolignano D, Greco M, Presta P, Duni A, Zicarelli M, Mercuri S, Pappas E, Lakkas L, Musolino M, Naka KK, Misiti R, Foti DP, Andreucci M, Coppolino G, Dounousi E

Blood purification7 Aug 2024Cited by 5 (Europe PMC)

PMID39111290DOI10.1159/000540303PepBankPUB-39111290

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Natural levels measured9

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In hemodialysis patients, circulating MOTS‑c levels were even higher in the 53 patients who had the combined endpoint of death or non-fatal cardiovascular events.
In plain wordsIn people on hemodialysis, higher levels of the body's own MOTS‑c were linked to later death or heart and blood vessel events.
Peptide
MOTS-c
Outcome
IncreaseCirculating MOTS-c in patients with the combined endpoint
Study
n = 94
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
MOTS-c levels were higher in HD patients than in controls (p < 0.001) and even more elevated (p = 0.01) in the 53 individuals experiencing the combined endpoint during follow-up (median duration: 26.5 months).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective, observational, multicenter study on 94 prevalent HD patients.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3911129002
02HumanEndogenous levelObservational studyOther
In hemodialysis patients, higher MOTS‑c was independently associated with the combined endpoint of mortality and non-fatal cardiovascular events in multivariate logistic regression.
In plain wordsIn people on hemodialysis, higher body's own MOTS‑c levels were linked to more death or heart and blood vessel events, after adjustment.
Peptide
MOTS-c
Outcome
IncreaseMOTS-c association with endpoint, multivariate logistic regression
Study
n = 94
Outcome group
Cardiovascular events · Cardiovascular
Measurements
OR
1.02 ratio
multivariate logistic regression
95% CI of OR
1.011 to 1.109 ratio
multivariate logistic regression
Source sentences
Summary
MOTS-c was independently associated with the endpoint at either multivariate logistic (OR 1.020; 95% CI: 1.011-1.109; p = 0.03) or Cox regression analyses (HR 1.004; 95% CI: 1.000-1.025; p = 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective, observational, multicenter study on 94 prevalent HD patients.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3911129003
03HumanEndogenous levelObservational studyOther
In hemodialysis patients, higher MOTS‑c was independently associated with the combined endpoint in Cox regression analysis.
In plain wordsIn people on hemodialysis, higher body's own MOTS‑c levels were linked to more death or heart and blood vessel events over follow-up.
Peptide
MOTS-c
Outcome
IncreaseMOTS-c association with endpoint, Cox regression
Study
n = 94
Outcome group
Cardiovascular events · Cardiovascular
Measurements
HR
1.004 ratio
Cox regression
95% CI of HR
1 to 1.025 ratio
Cox regression
Source sentences
Summary
MOTS-c was independently associated with the endpoint at either multivariate logistic (OR 1.020; 95% CI: 1.011-1.109; p = 0.03) or Cox regression analyses (HR 1.004; 95% CI: 1.000-1.025; p = 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective, observational, multicenter study on 94 prevalent HD patients.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3911129004
04HumanEndogenous levelObservational studyOther
In hemodialysis patients, adding MOTS‑c to prognostic models with other risk predictors significantly improved calibration.
In plain wordsIn people on hemodialysis, adding the body's own MOTS‑c level to risk models improved how well the models matched real outcomes.
Peptide
MOTS-c
Outcome
IncreaseModel calibration after adding MOTS-c
Study
n = 94
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
significantly improved the calibration, risk variability explanation, discrimination (receiver operating characteristic area under the curve from 0.727 to 0.743; C-index from 0.658 to 0.700), and particularly, the overall reclassification capacity (NRI 15.87%; p = 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective, observational, multicenter study on 94 prevalent HD patients.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3911129005
05HumanEndogenous levelObservational studyOther
In hemodialysis patients, adding MOTS‑c to prognostic models significantly improved the explanation of risk variability.
In plain wordsIn people on hemodialysis, adding the body's own MOTS‑c level to risk models helped explain more of the differences in risk.
Peptide
MOTS-c
Outcome
IncreaseRisk variability explanation after adding MOTS-c
Study
n = 94
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
significantly improved the calibration, risk variability explanation, discrimination (receiver operating characteristic area under the curve from 0.727 to 0.743; C-index from 0.658 to 0.700), and particularly, the overall reclassification capacity (NRI 15.87%; p = 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective, observational, multicenter study on 94 prevalent HD patients.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3911129006
06HumanEndogenous levelObservational studyOther
In hemodialysis patients, adding MOTS‑c raised the area under the ROC curve of the prognostic model from 0.727 to 0.743.
In plain wordsIn people on hemodialysis, adding the body's own MOTS‑c level made risk models slightly better at telling patients apart.
Peptide
MOTS-c
Outcome
IncreaseModel discrimination (AUC) after adding MOTS-c
Study
n = 94
Outcome group
Cardiovascular events · Cardiovascular
Measurements
ROC AUC without MOTS-c
0.727 AUC
prognostic model
ROC AUC with MOTS-c
0.743 AUC
prognostic model plus MOTS-c
Source sentences
Summary
discrimination (receiver operating characteristic area under the curve from 0.727 to 0.743; C-index from 0.658 to 0.700)
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective, observational, multicenter study on 94 prevalent HD patients.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3911129007
07HumanEndogenous levelObservational studyOther
In hemodialysis patients, adding MOTS‑c raised the C-index of the prognostic model from 0.658 to 0.700.
In plain wordsIn people on hemodialysis, adding the body's own MOTS‑c level made risk models better at ranking patients by risk.
Peptide
MOTS-c
Outcome
IncreaseModel discrimination (C-index) after adding MOTS-c
Study
n = 94
Outcome group
Cardiovascular events · Cardiovascular
Measurements
C-index without MOTS-c
0.658 C-index
prognostic model
C-index with MOTS-c
0.7 C-index
prognostic model plus MOTS-c
Source sentences
Summary
discrimination (receiver operating characteristic area under the curve from 0.727 to 0.743; C-index from 0.658 to 0.700)
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective, observational, multicenter study on 94 prevalent HD patients.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3911129008
08HumanEndogenous levelObservational studyOther
In hemodialysis patients, adding MOTS‑c improved the overall reclassification capacity of the prognostic model (NRI 15.87%).
In plain wordsIn people on hemodialysis, adding the body's own MOTS‑c level helped risk models place more patients in the right risk group.
Peptide
MOTS-c
Outcome
IncreaseOverall reclassification (NRI) after adding MOTS-c
Study
n = 94
Outcome group
Cardiovascular events · Cardiovascular
Measurements
NRI
15.87%
prognostic model plus MOTS-c
Source sentences
Summary
the overall reclassification capacity (NRI 15.87%; p = 0.01)
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective, observational, multicenter study on 94 prevalent HD patients.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3911129009
09HumanEndogenous levelObservational studyOther
In patients on chronic hemodialysis, circulating MOTS‑c levels were higher than in controls.
In plain wordsIn people on hemodialysis, the body's own MOTS‑c levels in blood were higher than in healthy controls.
Peptide
MOTS-c
Outcome
IncreaseCirculating MOTS-c in hemodialysis patients versus controls
Study
n: not reported in source
Comparator
Controls
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
MOTS-c levels were higher in HD patients than in controls (p < 0.001) and even more elevated (p = 0.01) in the 53 individuals experiencing the combined endpoint during follow-up (median duration: 26.5 months).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective, observational, multicenter study on 94 prevalent HD patients.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3911129001

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.